ArticleCureus2025
Alemtuzumab-Induced Resistant Thyroid Storm in a Patient With Graves' Disease Requiring Urgent Thyroidectomy: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 38-year-old woman with relapsing-remitting multiple sclerosis (RRMS) treated with alemtuzumab developed severe Graves' thyrotoxicosis presenting with palpitations, chest tightness, dizziness, and marked tachycardia with a heart rate of 160 per minute. Despite escalating antithyroid medications and beta-blockers, her condition progressed to thyroid storm that was resistant to medical therapy. Urgent total thyroidectomy was performed after preoperative euthyroidism was achieved with Lugol's iodine. Histopathology confirmed Graves' disease and revealed an incidental papillary thyroid carcinoma. This case is unique because it illustrates a rare instance of alemtuzumab-induced autoimmune thyroid disease progressing to treatment-refractory thyroid storm, further complicated by an incidental papillary thyroid carcinoma, an extremely uncommon coexistence. It highlights the need for heightened vigilance in monitoring alemtuzumab-treated patients for severe thyroid dysfunction and the importance of timely surgical intervention when medical therapy fails. Overall, it emphasizes that alemtuzumab-related thyrotoxicosis can evolve into a life-threatening treatment-resistant thyroid storm, and concurrent thyroid malignancy may be found incidentally, underscoring the value of multidisciplinary management and early surgical consideration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.